4BASEBIO PLC.
88Q.XETRA | Manufacture of pharmaceuticals, medicinal chemical and botanical products
4basebio AG, formerly 4basebio PLC, is a biotechnology company specializing in the design and manufacture of synthetic DNA for research, therapeutic, and diagnostic applications. The company focuses on producing high-purity, customized DNA products, including plasmid DNA (pDNA) and oligonucleotide D...Show More
Better Health for All
30
4basebio's core business is the design and manufacture of synthetic DNA for gene therapies, mRNA therapies, and DNA vaccines, which are applications with transformative health benefits.
1
The company has no reported products with negative health outcomes. In April 2025, 4basebio received MHRA GMP certification for the manufacture and supply of synthetic DNA for clinical use, indicating an outstanding safety record.
2
The company invested £40 million in November 2024 and secured £1.2 million (UK) / C$2.2 million (Canada) in funding for influenza vaccine development.
3
This vaccine development specifically targets improved protection against seasonal and emerging strains, demonstrating a focus on preventative health measures and preparedness for future pandemics.
4
Fair Money & Economic Opportunity
0
4basebio PLC is a biotechnology company specializing in synthetic DNA for research, therapeutic, and diagnostic applications. The provided articles focus on the company's ownership structure, financial performance (revenue, pretax loss, administrative costs), share transactions, and strategic progress in the life sciences sector. There is no evidence in the articles to suggest that 4basebio PLC offers any financial products or services, such as lending, deposits, or insurance, to consumers or businesses. Therefore, all KPIs related to 'Fair Money & Economic Opportunity' are not applicable to the company's core business model.
Fair Pay & Worker Respect
0
No specific, quantitative evidence was found across the provided articles for any of the KPIs related to Fair Pay & Worker Respect. Data points for living wage coverage, CEO to median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, and insecure contract share are not available.
1
While employee benefits such as a company pension scheme, enhanced maternity leave, and AXA Private Healthcare (including dental care and gym discount) are mentioned for UK-based team members, the percentage of the total global workforce covered by employer-funded health insurance is not specified.
2
The company's headcount was 84 at year-end 2023, with an expectation to exceed 100 by the end of 2024.
3
Fair Trade & Ethical Sourcing
0
The company does not procure or trade physical commodities, which results in a neutral score for both fair trade certification share and materials risk index.
1
While supplier auditing is mentioned as part of the procurement process, no specific frequency is provided.
2
The company states that supplier requirements regarding practices, guidelines, and values are an integral part of all procurement stages, including selection and auditing, but a percentage of contracts with enforceable ethical-sourcing clauses is not disclosed.
3
No incidents of forced or child labor are mentioned.
4
However, there is no specific data on traceability coverage, remediation speed for violations, or the procurement budget directed to diverse suppliers.
5
The company is subject to the Transparency Act, effective July 1, 2022, and engaged with EcoVadis in 2024.
6
Honest & Fair Business
-40
The company had one financial restatement in 2023 due to an error in accounting for a convertible bond agreement, which averages to 0.2 restatements per year over the past five years.
1
External audit coverage includes the parent company and UK subsidiaries by Crowe LLP, with a component auditor for the non-UK subsidiary 4basebio S.L.U., but the percentage of revenue, assets, or subsidiaries covered is not specified.
2
The board has members not considered independent, including Hansjörg Plaggemars, CEO of 2Invest AG (a significant shareholder), and Joe Fernandez (a significant shareholder).
3
The company has a Code of Conduct and corporate governance guidelines addressing ethical conduct and anti-corruption, but training frequency and effectiveness metrics are not provided.
4
The company engaged with EcoVadis, a sustainability rating provider, in 2024, indicating some level of independent verification of ethical claims.
5
Kind to Animals
-40
4basebio produces synthetic DNA, indicating zero animal inputs in its product line. However, its products are used in research involving animal models, including late pre-clinical and toxicology studies.
1
A partner, the University of Leicester, uses animal models for immunogenicity and efficacy evaluation and is legally responsible for complying with the Animals (Scientific) Procedures Act 1986 (ASPA).
2
While 4basebio's policy prohibits discretionary testing, it allows for legal mandates to override alternatives. The company's products are used in research involving animal models, but no specific animal testing volume is disclosed by 4basebio itself, leading to an assumption of high volume given the context of its products' use in preclinical and toxicology studies.
3
No War, No Weapons
0
The company, 4basebio PLC, specializes in synthetic DNA products for medical applications such as mRNA vaccines, therapeutics, viral vectors, and gene editing.
1
The provided articles consistently focus solely on these medical applications. There is no explicit information or evidence regarding the company's involvement in arms manufacturing, military contracts, conflict facilitation, or any related policies or investments. Therefore, no KPIs can be scored based on the provided evidence.
Planet-Friendly Business
-50
The company is not participating in any tracked climate initiatives.
1
There is no publicly available data on carbon emissions or reduction targets.
2
Respect for Cultures & Communities
0
No specific data points were provided in the articles for any of the KPIs related to Respect for Cultures & Communities.
1
The company's business model is described as fundamentally neutral regarding direct impacts on cultures and communities, resulting in low materiality.
2
The company engaged with EcoVadis, a sustainability rating provider, in 2024.
3
Safe & Smart Tech
-10
The company has no documented incidents of unauthorized data use and states it exchanges information for fraud protection and crime prevention.
1
Users can withdraw consent and request data access, rectification, deletion, restriction, and data portability.
2
Unsuccessful applicant details are held for 12 months, while Google Analytics cookies are saved for 12 months, Hubspot cookies for 6 months, Cloudfare cookies for 1 hour, and Brighter IR cookies for 5 days.
3
The company received its GMP manufacturing licence from the UK regulator, the Medicines and Healthcare products Regulatory Agency, and states a commitment to compliance with relevant laws and regulations.
4
Zero Waste & Sustainable Products
0
No specific, concrete data points or initiatives related to waste diversion, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audits, zero waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education for 4BASEBIO PLC are provided in the available articles.
1
While the company has engaged with EcoVadis for sustainability ratings, no actual ratings or specific performance metrics relevant to these KPIs are disclosed.
2